Medicare Part D plans will look to tighten their management of drug costs in the next couple of years as the benefit redesign established by the Inflation Reduction Act shifts more of the financial burden of coverage from Medicare to plans.
Starting in 2025, plan responsibility for branded drug costs in the catastrophic phase will increase from the current 15% to 60%, while